Demonstrating the value of RWEA new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional Share XDemonstrating the value of RWEhttps://pharmaphorum.com/views-analysis-oncology/demonstrating-the-value-of-rwe/
Q&A: Draper’s Jenna Balestrini on the future of CAR-TAs exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential. Jenna Share XQ&A: Draper’s Jenna Balestrini on the future of CAR-Thttps://pharmaphorum.com/views-analysis-oncology/qa-drapers-jenna-balestrini-on-the-future-of-car-t/
The state of personalised medicine in 2019Things are good, and they’re getting better. When researchers completed mapping the human genome in 2003, it broke Share XThe state of personalised medicine in 2019https://pharmaphorum.com/views-analysis-oncology/the-state-of-personalised-medicine-in-2019/
ESMO 2019 roundupThe European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma Share XESMO 2019 rounduphttps://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/
Transforming oncology with a pan-European approach to data sharingBetween genomic data, electronic health records and digital health tools, we have all the information we need to Share XTransforming oncology with a pan-European approach to data sharinghttps://pharmaphorum.com/views-analysis-oncology/transforming-oncology-with-a-pan-european-approach-to-data-sharing/
The Japanese healthcare revolutionSomething that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and Share XThe Japanese healthcare revolutionhttps://pharmaphorum.com/views-analysis-oncology/the-japanese-healthcare-revolution/
The promise and pitfalls of molecular testing in oncologyGreat strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain Share XThe promise and pitfalls of molecular testing in oncologyhttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/research-partnership-molecular-testing-cancer/
Smarter thinking about pharmaceutical marketingRobb DeFilippis, from end-to-end global creative production and sourcing partner Tag, discusses how a more effective multichannel pharma Share XSmarter thinking about pharmaceutical marketinghttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/tag-pharmaceutical-marketing-production/
NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
